Q1 2023 Earnings Presentation
FY 2023 GUIDANCE
FY 2023 Outlook
Increasing FY 2023 Guidance
Revenue (in $B)
Reported Growth
Organic Growth
Constant Currency Growth
Non-GAAP EPS
Non-GAAP EPS Growth
2023 Bruker
$2.83 to $2.88 billion
(from $2.81-$2.86B)
12% to 14% (from 11%-13%)
9% to 11% (from 8%-10%)
11% to 13% (from 9.5%-11.5%)
$2.55 to $2.60
(from $2.52 - $2.57)
9% to 11%
(from 8%-10%)
FY 2023 Non-GAAP Assumptions (as of May 4, 2023)
Operating profit growth 8%-10%;
■ Operating margin decline ~70 bps
BRUKER
Accelerating R&D to ~10% of revenue, with focus
on proteomics and spatial biology
Organic operating margin increase ~50 bps
Transitory 2023 headwind of ~120 bps to operating
margin from FX and acquisitions
■ Effective tax rate: 28%
■CAPEX: $130M
FX assumptions (rates as of March 31, 2023):
EUR = 1.086 USD; CHF = 1.094 USD; Yen = 0.0075 USD
Q1 2023 Earnings Presentation |
May 4, 2023
I
15View entire presentation